The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of molecular subtypes with pathologic response in a phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy (NAC) for localized, muscle-invasive bladder cancer (SWOG S1314; NCT02177695).
 
Seth P. Lerner
Honoraria - Dava Oncology; MSD; Nucleix
Consulting or Advisory Role - Anchiano; Ferring; Merck Sharp & Dohme; miR Scientific; QED Therapeutics; Roche/Genentech; Urogen pharma; Vaxiion; Verity Pharmaceuticals
Research Funding - Endo Pharmaceuticals; FKD Therapies; Japan BCG Laboratory; Roche/Genentech; Urogen pharma; Vaxiion; Viventia Biotech
Patents, Royalties, Other Intellectual Property - TCGA expression subtype singel patient classifier
Travel, Accommodations, Expenses - Dava Oncology; Ferring; MSD; Nucleix
 
David James McConkey
Honoraria - BioClin Therapeutics; H3 Biomedicine; Janssen Oncology
Research Funding - AstraZeneca; BioClin Therapeutics
Travel, Accommodations, Expenses - BioClin Therapeutics; H3 Biomedicine
 
Catherine Tangen
No Relationships to Disclose
 
Joshua J Meeks
Honoraria - CG Oncology; Janssen
Consulting or Advisory Role - AstraZeneca; Ferring; Merck
Research Funding - Epizyme; Merck Sharp & Dohme
Travel, Accommodations, Expenses - AstraZeneca; Merck Sharp & Dohme
 
Thomas W. Flaig
Leadership - Aurora Oncology
Stock and Other Ownership Interests - Aurora Oncology
Honoraria - BN ImmunoTherapeutics
Consulting or Advisory Role - GTX
Research Funding - Agensys; Aragon Pharmaceuticals; Astellas Pharma; astrazeneca/MedImmune; Bavarian Nordic; Bristol-Myers Squibb; Dendreon; Exelixis; GTx; Janssen Oncology; La Roche-Posay; Lilly; Medivation; Merck; Novartis; Pfizer; Roche/Genentech; Sanofi; Seagen; Sotio; Tokai Pharmaceuticals
Patents, Royalties, Other Intellectual Property - The University of Colorado has filed 2 patents related in which I am an inventor. These are related to early-stage bladder cancer treatment and detection. Neither is commercialized or licensed at this time.
 
Xing Hua
No Relationships to Disclose
 
Siamak Daneshmand
Stock and Other Ownership Interests - Taris
Honoraria - Aduro Biotech; Allergan (I); Bristol-Myers Squibb; Ferring; Janssen; Johnson & Johnson; Nucleix; Olympus; pacific edge; Photocure; QED Therapeutics; Seagen; Spectrum Pharmaceuticals
Consulting or Advisory Role - Ferring; Photocure; QED Therapeutics; Taris
Research Funding - Photocure
Travel, Accommodations, Expenses - Photocure
 
Ajjai Shivaram Alva
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck; Pfizer
Speakers' Bureau - AstraZeneca
Research Funding - Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Harpoon Therapeutics (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Progenics (Inst); Progenics (Inst); Prometheus (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck
 
M. Scott Lucia
Stock and Other Ownership Interests - 3D Biopsy
Consulting or Advisory Role - MDxHealth
 
Dan Theodorescu
Stock and Other Ownership Interests - Aurora Oncology; Machavert Pharmaceuticals; Urogen Pharma
Honoraria - Machavert Pharmaceuticals; Merck; Urogen pharma
Consulting or Advisory Role - Aurora Oncology; Machavert Pharmaceuticals; Merck; Urogen Pharma
Patents, Royalties, Other Intellectual Property - ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME Pub No. US 2017/0204112 A1 Pub. Date: July 20,2017
Travel, Accommodations, Expenses - Machavert Pharmaceuticals; Merck; Urogen Pharma
 
Amir Goldkorn
Consulting or Advisory Role - Acadia Wood
Research Funding - Angle; Clearbridge Biomedics; Cynvenio Biosystems; Menarini Silicon Biosystems; RareCyte; Thermo Fisher Scientific
Patents, Royalties, Other Intellectual Property - I am listed as a co-inventor on a patent held jointly by USC and Caltech for a microfilter we developed for capturing live circulating tumor cells from blood.
 
Matthew I. Milowsky
Consulting or Advisory Role - BioClin Therapeutics
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Incyte (Inst); Innocrin Pharma (Inst); Inovio Pharmaceuticals (Inst); Jounce Therapeutics (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst); Syndax (Inst); X4 Pharma (Inst)
Other Relationship - Asieris Pharmaceuticals (Inst)
 
Woonyoung Choi
No Relationships to Disclose
 
Richard Carlton Bangs
Consulting or Advisory Role - Bristol-Myers Squibb; Incyte
Travel, Accommodations, Expenses - Bristol-Myers Squibb
Other Relationship - American Institutes for Research; Facing our Risk of Cancer Empowered; National Cancer Institute; National Cancer Institute; NCI; Summa Health System; SWOG; SWOG; University of Puerto Rico; University of Puerto Rico
 
Daniel Gustafson
No Relationships to Disclose
 
Ian Murchie Thompson
Consulting or Advisory Role - Magforce; Profound Medical
Patents, Royalties, Other Intellectual Property - I have several patents with colleagues involving novel biomarkers for cancer and two devices for sexual dysfunction and urinary incontinence. No revenues at this time and our University IP office is working with industry to determine if these can be comme